Abstract 128P
Background
Tislelizumab, an investigational monoclonal antibody with high affinity and specificity for PD-1, was engineered to minimize binding to FcγR on macrophages in order to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. In prior reports, tislelizumab, as a single agent and in combination with various chemotherapies, was generally well tolerated and had antitumor activity in pts with advanced solid tumors. This phase 2 study (NCT03469557) assessed tislelizumab plus chemotherapy as first-line therapy in pts with inoperable, locally advanced, or metastatic GC/GEJC or ESCC.
Methods
Patients with GC/GEJC received tislelizumab (200 mg IV Q3W) + oxaliplatin (130 mg/m2 IV Q3W for ≤6 cycles) and capecitabine (1000 mg/m2, Days 1-15 orally BID Q3W); pts with ESCC received tislelizumab + cisplatin (80 mg/m2 IV Q3W for ≤6 cycles) and 5FU (800 mg/m2/d, Days 1-5 IV Q3W for ≤6 cycles). Response was assessed using RECIST v1.1, Kaplan-Meier analysis estimated survival, and adverse event (AE) monitoring examined safety/tolerability.
Results
As of 31 Mar 2019, 30 pts with GC/GEJC and ESCC (n = 15 each) were enrolled. Median age was 61 yr; most pts were male (n = 25). Clinical responses were observed during treatment (Table). In pts with ESCC, treatment-emergent AEs (TEAEs) of grade ≥3 occurring in ≥ 2 pts were vomiting and dysphagia (n = 4 each), hyponatremia (n = 3), and anemia, leukopenia, fatigue, lung infection, and decreased weight (n = 2 each). No grade ≥3 TEAEs occurred in ≥ 2 pts with GC/GEJC. One pt with ESCC had a fatal AE (hepatic dysfunction) attributed to treatment by the investigator, but which may have been confounded by progressive disease and underlying hepatitis.Table:
128P
GC/GEJC (n = 15) | ESCC (n = 15) | |
---|---|---|
PR, n (%) | 7 (46.7) | 7 (46.7) |
SD, n (%) | 3 (20.0) | 5 (33.3) |
PD, n (%) | 1 (6.7) | 0 (0.0) |
Non-CR/non-PD, n (%)* | 2 (13.3) | 0 (0.0) |
NE, n (%) | 2 (13.3) | 3 (20.0) |
ORR, % (95% CI) | 46.7 (21.3, 73.4) | 46.7 (21.3, 73.4) |
Median DoR, (95% CI) | NR (3.0, NR) | 12.8 (3.5, 12.8) |
Median PFS, mo (95% CI) | 6.1 (3.8, NR) | 10.4 (5.6, 15.1) |
Median OS, mo (95% CI) | NR (7.0, NR) | NR (5.6, NR) |
Median follow-up, mo (95% CI) | 15.4 (14.7, 17.2) | 13.0 (12.3, 14.0) |
Patients who have non-target lesions at baseline.
Abbreviations: CI, confidence interval; CR, complete response; DoR, duration of response; ESCC, esophageal squamous cell carcinoma; GC/GEJC, gastric/gastroesophageal junction cancer; mo, month; NE, not evaluable; NR, not reached; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.
Conclusions
Tislelizumab plus chemotherapy was generally well tolerated and antitumor activity was observed in pts with advanced GC/GEJC or ESCC.
Clinical trial identification
NCT03469557.
Editorial acknowledgement
Writing and editorial support for this abstract was provided by Agnieszka Laskowski, PhD, and Elizabeth Hermans, PhD, of OPEN Health Medical Communications (Chicago, IL).
Legal entity responsible for the study
BeiGene Co., Ltd., Beijing, China.
Funding
BeiGene (Beijing) Co., Ltd., Beijing, China.
Disclosure
X. Li: Full / Part-time employment: BeiGene (Beijing) Co., Ltd. Y. Li: Full / Part-time employment: BeiGene (Beijing) Co., Ltd. X. Wang: Full / Part-time employment: BeiGene (Beijing) Co., Ltd. S. Yang: Full / Part-time employment: BeiGene (Beijing) Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
427P - Sahai: A restorative support to address unmet needs of women with cancer – impact on quality of life
Presenter: Poonam Maurya
Session: Poster display session
Resources:
Abstract
428P - A pilot study on comparative efficacy of tramadol or eutectic mixture of local anaesthetics (prilocaine plus lignocaine) in preventing bone marrow aspiration associated pain
Presenter: Bipinesh Sansar
Session: Poster display session
Resources:
Abstract
429P - Skin pathologic change evaluation of the patients who had EGFR inhibitor-related skin adverse events
Presenter: Sung Yong Oh
Session: Poster display session
Resources:
Abstract
430P - Emetic risk of carboplatin plus pemetrexed is higher than that of carboplatin plus paclitaxel in patients with lung cancer: A propensity score-matched analysis
Presenter: Koichi Matsuo
Session: Poster display session
Resources:
Abstract
431P - An in vitro evaluation of CYP2D6 enzymatic inhibition activities of a Chinese herbal medicine formulation (Xiang Bei Yangrong Tang) for the management of cancer-related fatigue
Presenter: Ning Yi Yap
Session: Poster display session
Resources:
Abstract
432P - Chemotherapy induced extravasation: Incidence and possible predictors
Presenter: Shalaka Somayaji
Session: Poster display session
Resources:
Abstract
433P - Prospective outcomes of adolescent and young adult (AYA) patients received treatment from a tertiary cancer hospital in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: Poster display session
Resources:
Abstract
434P - Pneumonitis induced antineoplastic agents: Mortality and risk factors in 129 consecutive cases
Presenter: Sawako Kaku
Session: Poster display session
Resources:
Abstract
435P - Telephonic communication in palliative care for better management of terminal cancer patients in rural India: An NGO based approach
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
436P - Assessing the quality of life of Filipino cancer patients: A survey of Filipino oncologists
Presenter: Frederic Ivan Ting
Session: Poster display session
Resources:
Abstract